To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Exclusion Criteria

• •Contraindication to receive vadadustat per United States prescribing information (USPI) as determined by the treating health care provider.
• •Concomitant use of any hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI).
• •Known cirrhosis or active, acute liver disease.
• •Unable to comply with study requirements or compliance with attending dialysis treatments as prescribed, or in the opinion of the treating physician or Investigator, not clinically stable to participate in the study.
• •Pregnant at the time of consent (per participant self-report).
• •Any other reason, which in the opinion of the Investigator, would make the participants unsuitable for participation in the study.
• •History of, or currently diagnosed with, any hematological disease, such as sickle cell disease, thalassemia, hemochromatosis, Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, myelodysplastic syndromes, or any other blood disorder that could interfere with the study outcomes.
• •Participants will receive a blood transfusion within 3 months prior to the initiation of the study.
• •History of or currently diagnosed with chronic lung disease